Patent 11801238 was granted and assigned to Deciphera Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.
Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.